Access Pharmaceuticals Inc

2600 Stemmons Frwy Suite 176, Dallas, TX 75207

Access Pharmaceuticals, Inc. is a development-stage pharmaceutical company focused on developing both novel low-development risk product candidates, and technologies with longer-term major product opportunities. The Company has proprietary patents or rights to five technology platforms: synthetic polymers, bioerodible hydrogels, Residerm, carbohydrate-targeting technology and agents for the prevention and treatment of viral disease, including HIV. Its partner, GlaxoSmithKline is marketing Aphthasol in the United States, a drug jointly developed for the treatment of canker sores. The Company has licensed certain of the rights to amlexanox for the treatment of canker sores from GlaxoSmithKline for certain countries and the worldwide rights for additional indications, including mucositis and oral diseases. The Company is also developing Polymer Platinate, a chemotherapeutic agent believed to have significantly reduced toxicity and superior efficacy in treating cancers.

Albany Molecular Research, Inc
(AMRI) 6.27

21 Corporate Circle, PO Box 15098, Albany, NY 12212-5098 7001 Performance Drive, Syracuse, NY 13212 601 E. Kensington Road, Mount Prospect, IL 60056 18804 North Creek Parkway, Bothell, WA 98011

Albany Molecular Research, Inc. is a chemistry-based drug discovery and development company, focusing on applications for new small molecule prescription drugs. The company conducts R&D projects and collaborates with many leading pharmaceutical, biotechnology and genomics companies, and is developing new chemistry technology for potential prescription drug applications.

Algos Therapeutics

1360 Energy Park Drive, Suite 300, Saint Paul, MN 55108

Algos Therapeutics is a privately held, independent research company specializing in the evaluation of potential pain treatments under development. The data we generate from our models have proven highly predictive for activity in human pain. And, the information derived is invaluable for the discovery of potential breakthrough treatments for pain. This is a vital component of our clients’ pain research programs.

Athersys

3201 Carnegie Ave, Cleveland, OH 44115

Athersys is a functional genomics and biopharmaceutical company engaged in the development, application and commercialization of novel gene expression tools and therapeutic products. The companyís research and development programs are focused on its two proprietary platform technologies: RAGE (Random Activation of Gene Expressionô) and SMCô (Synthetic Microchromosomeô) vector system. These technologies can be used for providing gene therapy targets, antibody targets and small molecule drug targets.

CellzDirect
*VENDOR/SERVICE*

480 Hillsboro St., Suite 130, Pittsboro NORTH CAROLINA 27312 1624 Headway Circle, Suite 100, Austin TEXAS 78754

CellzDirect is a biotech company providing in vitro hepatic cell products and contract laboratory and consulting services to drug discovery and development scientists worldwide. We offer a complete line of high quality fresh hepatocytes, cryopreserved hepatocytes and liver subcellular fractions. Our service offerings include drug-drug interaction studies, drug metabolism studies, and hepatotoxicity assays in both GLP and non-GLP formats. With CellzDirect’s support, scientists are better able to conduct research that accelerates the discovery of safe and effective drugs.

ChanTest, Inc.
*VENDOR/SERVICE*

14656 Neo Parkway, Cleveland OHIO 44128

ChanTest's primary focus is on ion channels that may be either deliberate therapeutic targets or unintended targets resulting in unwanted side effects. In particular, drug-induced blockade of cardiac potassium channels may be lead to impaired delayed repolarization, QT prolongation and torsades de pointes. ChanTest has pioneered the hERG potassium channel assay as a preclinical predictor of delayed repolarization.

Encysive Pharmaceuticals
(ENCY) 0.00

4848 Loop Central Drive, 7th Floor, Houston, TX 77081

Encysive Pharmaceuticals is a pharmaceutical company that discovers, develops and commercializes small molecule drugs aimed at cardiovascular and inflammatory diseases. Our research strategy focuses on the vascular endothelium, because of its importance in the evolution of a number of serious diseases for which current therapies are inadequate.

Golden Helix, Inc.
*VENDOR*

716 S 20th Avenue, Suite 102, Bozeman, MT 59718

Golden Helix, Inc. produces subject-specific, data mining software. Products are available for pharmacogenomics and intelligent, target-specific compound selection. The mission of Golden Helix, Inc. is to be the leader in subject-specific data mining software in the life sciences.

Hematech

4401 South Technology Drive, Sioux Falls, SD 57106 3483 US 75 Avenue Hull, IA 51239

Whether developing treatments for antibiotic-resistant infections or producing new drugs to help defend against bio-terrorism, Hematech, Inc. is utilizing the latest advances in technology to help fight diseases. The company is currently developing cows that can efficiently produce human antibodies. The genetically altered cows, known as TC Cows™, will be used for the production of large quantities of polyclonal antibodies. These antibodies are expected to help in the treatments of viral or bacterial infections, autoimmune disorders and other medical conditions occurring in humans.

Immtech Intl Inc
(IMM) 0.00

One North End Avenue, New York, NY 10282 150 Fairway Drive, Suite 150, Vernon Hills, IL 60061

Immtech is discovering, developing and commercializing drugs for the treatment of: (i) fungal and other infectious diseases such as tuberculosis, hepatitis, pneumonia, diarrhea and AIDS and (ii) cancer, through both the Company's pharmaceutical program, operated by a joint venture company, NextEra Therapeutics, Inc., its biological program. The Company has two disciplines for developing new drugs, a pharmaceutical program and a biological program. The pharmaceutical program focuses on the discovery, development and commercialization of drugs to treat fungal, parasitic, bacterial and viral diseases. The biological program is operated through a joint venture with the Franklin Research Group in a Company called NextEra.

Integrated Genomics

2201 W Campbell Park Dr, Chicago, IL 60612

Founded in 1997, Chicago-based Integrated Genomics specializes in research in microbial genomics, biochemistry, and gene expression. Our scientists have broad experience in both in silico and wet lab sequencing, research and development with more than 100 relevant publications in these areas. Integrated Genomics has particularly long-standing relationships and active research in the area of lactic acid bacteria and pathogenic microbes, as well as a broad customer base across industry, academic and government institutions. Integrated Genomics’ products and services are based on ERGO™, our web-based genome analysis platform. ERGO™ integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data with publicly available information. Focused on microbial genomics, ERGO™ provides better and faster identification of gene function across all organisms.

Introgen Therapeutics Inc
(INGN.PK) 0.00

301 Congress Avenue, Ste. 1850, Austin, Texas 78701

Introgen Therapeutics (NASDAQ: INGN) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. We are developing product candidates to treat a wide range of cancers using tumor suppressors, genes, cytokines and other molecular agents. Our products are designed to increase production of normal cancer-fighting proteins that act to overpower cancerous cells, stimulate immune activity, or directly kill cancer cells. Introgen's therapies can be used alone, but also enhance conventional cancer therapies such as surgery, chemotherapy, radiation and monoclonal antibodies.

King Pharmaceuticals Inc
*SPECIALTY/GENERIC*
(KG) 9.14

501 Fifth Street, Bristol, TN 37620

King Pharmaceuticals, established in 1994, is a vertically integrated branded pharmaceutical company that develops, manufactures and markets therapies and technologies primarily in cardiovascular/metabolics, neuroscience, and hospital/acute care. King has unique strengths in commercialization, advanced clinical development, manufacturing, and regulatory affairs, which make the company a proven partner of choice for late stage compounds and novel branded prescription pharmaceutical products and technologies.

LabNow

Barton Oaks Plaza Two, 901 S. Mopac, Suite 100, Austin, TX 78746

LabNow, Inc., seeks to improve global health and safety through the deployment of simple, rapid, point-of-need laboratory testing. The company, headquartered in Austin, Texas, has licensed novel, platform lab-on-a-chip sensor technology from The University of Texas at Austin (UT). The technology has the capability to automate complex fluid analysis quickly, accurately and at lower cost than current methods. The microfluidics sensor technology has broad uses in medical, homeland security, environmental chemistry and process engineering applications.

Lexicon Pharmaceuticals, Inc.
(LXRX) 1.49

8800 Technology Forest Place The Woodlands, TX 77381-1160 350 Carter Road Princeton, NJ 08540

Lexicon is focused on the discovery and development of breakthrough treatments for human disease. We have used our proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease.

Ligocyte Pharmceuticals

2155 Analysis Drive Bozeman, MT 59718

LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system. Immunomodulatory drugs represent one of the most exciting areas of pharmaceutical research today, addressing the disease process itself rather than simply treating the resulting symptoms.

Luminex
*VENDOR*
(LMNX) 14.99

12212 Technology Blvd, Austin, TX 78727

Luminex® Corporation was incorporated in May 1995 and began commercial production of our first generation system in 1997. Luminex develops, manufactures and markets innovative biological testing technologies with applications throughout the life-sciences industry. The company’s open-architecture xMAP® technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately. Systems using xMAP technology (formerly known as LabMAP®) perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. Using lasers and high-speed digital-signal processors, the analyzer simultaneously identifies the bioassay and measures the results, all in real time.

MGI Pharma, Inc.

5775 West Old Shakopee Road, Suite 100, Bloomington, MN 55437

MGI PHARMA is an oncology-focused biopharmaceutical company that acquires, develops and commercializes differentiated products that address the unmet needs of cancer patients.

Mirus Bio Corporation

505 S. Rosa Road, Suite 104, Madison, WI 53719-1267

Mirus Bio Corporation is a biopharmaceutical company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products. Under development are RNAi gene silencing therapies based on Mirus’ proprietary Dynamic PolyConjugates™ delivery platform and gene therapies utilizing its Pathway IV™ delivery protocol. Commercially, Mirus markets a range of innovative transfection and labeling research reagents worldwide.

Neopharm Inc.
(NEOL.PK) 0.28

1850 Lakeside Drive, Waukegan, IL 60085

NEOPHARM is dedicated to the discovery, development and commercialization of new and innovative cancer drugs for therapeutic applications. NEOPHARM has built its drug portfolio based on its two novel proprietary technology platforms: a tumor-targeting platform and the NeoLipid® drug delivery system.

Northfield Laboratories, Inc.
(NFLDQ.PK) 0.04

1560 Sherman Avenue, Evanston, IL 60201-4800

Northfield Laboratories Inc. is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. Northfield’s product, PolyHeme®, is a human hemoglobin-based temporary oxygen-carrying red blood cell substitute. PolyHeme® simultaneously restores lost blood volume and hemoglobin levels and is designed for rapid, massive infusion. PolyHeme® requires no cross-matching. It is compatible with all blood types and therefore immediately available for infusion. It has an extended shelf life in excess of 12 months.

Power3 Medical Products

3400 Research Forest Drive, Suite B2-3, The Woodlands, TX 77381

Power3 Medical is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases. The research platform is centered on the study of proteomics, the science of protein interactions within living cells.

Repros Therapeutics, Inc.
(RPRX) 0.54

2408 Timberloch Place, B-7, The Woodlands, TX 77380

We are a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Transgenomic
*VENDOR/SERVICE*
(TBIO.OB) 0.43

12325 Emmet Street, Omaha, NE 68164 Z.A. de la Clef Saint Pierre, 10B, Rue Blaise Pascal, 78990 Elancourt, France

TRANSGENOMIC is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offering includes systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

VisiGen Biotechnologies, Inc.

2575 West Bellfort, Suite 250, Houston, TX 77054

VisiGen Biotechnologies, Inc., a privately-held company based in Houston, TX, is developing a radically new method of sequencing DNA that is projected to completely sequence a human genome in a day for the long-coveted target mark of $1000. The Company owns the IP related to its DNA sequencing technology. Its technology is distinguished from other next generation sequencing technologies in that it exploits the natural process of DNA replication in a way that enhances accuracy without drastically impacting efficiency. VisiGen’s approach involves engineering both polymerase and nucleotide triphosphates to act together as direct molecular sensors of DNA base identity in real-time. The massively parallel nature of this technology is projected to enable sequence acquisition at rates approaching 1 million bases per second per machine.

Xenogen Biosciences
*SERVICE*

68 Elm Street, Hopkinton, MA 01748 5 Cedar Brook Drive Cranbury, NJ 08512

Xenogen Biosciences, a subsidiary of Xenogen Corporation, has a long and respected track record in the design and production of genetic modifications in animal models using pronuclear microinjection and/or gene knockout/knockin techniques, and breeding services. To date, Xenogen has produced over 8,000 unique transgenic mice and rats from over 2,500 transgene constructs. More than 97% of all gene constructs have successfully produced transgenic mice and rats, or gene knockout lines. In sum, Xenogen offers the biomedical community a long-proven and integrated array of genetically-modified animal creation capabilities, as well as a comprehensive phenotyping platform to characterize such animal lines, and an in vivo compound profiling program to characterize the effects of compounds in rodent models.

ZymeTx, Inc.

Post Office Box 890666, Oklahoma City, OK 73189-0666

ZymeTx, Inc. is a biotechnology company engaged in the development, distribution and introduction of novel solutions for the diagnosis, treatment and surveillance of infectious viral diseases. These products include the ZstatFlu® Rapid Test for Influenza A and B, ViraStat® Parainfluenza Laboratory Test, and the National Flu Surveillance Network - NFSN®.